Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $85.3 million.

  • Abivax's Shares Outstanding (Diluted Average) rose 2281.21% to $85.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.3 million, marking a year-over-year increase of 2281.21%. This contributed to the annual value of $67.4 million for FY2024, which is 4461.88% up from last year.
  • Per Abivax's latest filing, its Shares Outstanding (Diluted Average) stood at $85.3 million for Q3 2025, which was up 2281.21% from $71.8 million recorded in Q2 2025.
  • Over the past 5 years, Abivax's Shares Outstanding (Diluted Average) peaked at $85.3 million during Q3 2025, and registered a low of $738.73 during Q1 2024.
  • Over the past 5 years, Abivax's median Shares Outstanding (Diluted Average) value was $32.9 million (recorded in 2022), while the average stood at $37.7 million.
  • In the last 5 years, Abivax's Shares Outstanding (Diluted Average) soared by 1016.79% in 2022 and then soared by 512946454.14% in 2025.
  • Abivax's Shares Outstanding (Diluted Average) (Quarter) stood at $17.7 million in 2021, then rose by 10.17% to $19.5 million in 2022, then surged by 137.88% to $46.3 million in 2023, then surged by 45.4% to $67.4 million in 2024, then rose by 26.58% to $85.3 million in 2025.
  • Its last three reported values are $85.3 million in Q3 2025, $71.8 million for Q2 2025, and $873.06 during Q1 2025.